Answers are grounded in this paper and cite their sources.
Systematic review shows no increased psychiatric risks with GLP-1 use, suggesting positive quality-of-life improvements.
Use of glucagon‐like peptide 1 (GLP‐1) receptor agonists in patients with diabetes and/or obesity did not increase risk of psychiatric adverse effects or worsening depressive symptoms, a systematic review and meta‐analysis has found. Use of GLP‐1s in these populations also improved several quality‐of‐life outcomes. Results of the review and meta‐analysis were published online May 14, 2025, in JAMA Psychiatry .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: